{"filing":{"accession_number":"0001493152-26-036486","cik":"0001712762","ticker":"BIAFW","company_name":"bioAffinity Technologies, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/form8-k.htm"},"events":[{"id":26197,"run_id":23794,"accession_number":"0001493152-26-036486","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 disclosing financial results and business highlights. The press release (Exhibit 99.1) reports revenue of $1.5 million for Q2 2026 (19% increase YoY), net loss of $3.4 million, and detailed operational metrics including 216% YoY growth in CyPath Lung test volume. The filing is structured as Item 2.02 with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures on Form 8-K.","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27230,"accession_number":"0001493152-26-036486","item_number":"2.02","item_title":"and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results and business highlights. The press release (Exhibit 99.1) reports revenue of $1.5 million for Q2 2026 (19% increase YoY), net loss of $3.4 million, and detailed operational metrics including 216% YoY growth in CyPath Lung test volume. The filing is structured as Item 2.02 with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:16:03.389848+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27230,"accession_number":"0001493152-26-036486","item_number":"2.02","item_title":"and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 disclosing financial results and business highlights. The press release (Exhibit 99.1) reports revenue of $1.5 million for Q2 2026 (19% increase YoY), net loss of $3.4 million, and detailed operational metrics including 216% YoY growth in CyPath Lung test volume. The filing is structured as Item 2.02 with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures on Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T02:16:03.389848+00:00","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-08-07"}]}